Annotation Detail

Information
Associated Genes
PIK3CA
Associated Variants
PIK3CA p.His1047Arg (p.H1047R) ( ENST00000263967.4, ENST00000643187.1 )
PIK3CA p.His1047Arg (p.H1047R) ( ENST00000263967.4, ENST00000643187.1 )
Associated Disease
head and neck cancer
Source Database
CIViC Evidence
Description
Xenografts from one head and neck cancer cell line (CAL-33) with a PIK3CA H1047R mutation were more sensitive to the combined inhibition of PI3K/mTOR and EGFR with BEZ-235 and cetuximab (N=9) than cetuximab (N=9, P=0.0039) or BEZ-235 alone (N=9, P=0.0002) in-vivo.
Variant Origin
somatic
Variant Origin
Somatic
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/1363
Gene URL
https://civic.genome.wustl.edu/links/genes/37
Variant URL
https://civic.genome.wustl.edu/links/variants/107
Rating
2
Evidence Type
Predictive
Disease
Head And Neck Cancer
Evidence Direction
Supports
Drug
Dactolisib,Cetuximab
Evidence Level
D
Clinical Significance
Sensitivity/Response
Pubmed
23619167
Drugs
Drug NameSensitivitySupported
CetuximabSensitivitytrue
DactolisibSensitivitytrue